1
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------
FORM 10-Q
[X] Quarterly report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the quarterly period ended March 31, 1997
[ ] Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the transition period from_________________to _______________
Commission file number 1-9957
Diagnostic Products Corporation
(Exact name of registrant as specified in its charter)
CALIFORNIA 95-2802182
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
5700 WEST 96TH STREET
LOS ANGELES, CALIFORNIA 90045
(Address of principal executive offices)
Registrant's telephone number: (213) 776-0180
NO CHANGE
(Former name, former address and former fiscal year,
if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
[ YES X ][NO ]
The number of shares of Common Stock, no par value, outstanding as of March
31, 1997, was 13,613,818.
================================================================================
2
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS.
DIAGNOSTIC PRODUCTS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(In thousands, except per share data) Three Months Ended
March 31,
-------------------------
1997 1996
-------- --------
SALES $ 44,400 $ 43,246
-------- --------
COSTS AND EXPENSES:
Cost of sales 19,682 18,088
Selling 8,659 8,057
Research and development 4,756 4,384
General and administrative 5,526 4,649
Equity in income of affiliates (281) (446)
Investment income (315) (407)
-------- --------
Total costs and expenses 38,027 34,325
-------- --------
INCOME BEFORE INCOME TAXES 6,373 8,921
PROVISION FOR INCOME TAXES 1,710 2,420
-------- --------
NET INCOME $ 4,663 $ 6,501
======== ========
NET INCOME PER SHARE $ .34 $ .47
WEIGHTED AVERAGE SHARES
AND EQUIVALENTS OUTSTANDING 13,867 13,942
1
3
DIAGNOSTIC PRODUCTS CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Dollars in Thousands) March 31, December 31,
1997 1996
--------- ---------
ASSETS (Unaudited)
CURRENT ASSETS:
Cash and cash equivalents $ 7,425 $ 13,781
Accounts receivable - net of allowance for
doubtful accounts of $82 and $76 49,279 45,631
Inventories 45,181 42,828
Prepaid expenses and other current assets 145 375
Deferred income taxes 3,663 3,663
--------- ---------
Total current assets 105,693 106,278
PROPERTY, PLANT AND EQUIPMENT:
Land and buildings 29,067 29,195
Machinery and equipment 46,387 46,043
Leasehold improvements 6,726 6,701
Construction in progress 770 700
--------- ---------
Total 82,950 82,639
Less accumulated depreciation and amortization 37,756 37,192
--------- ---------
Property, plant and equipment - net 45,194 45,447
SALES-TYPE AND OPERATING LEASES 22,361 22,056
DEFERRED INCOME TAXES 2,772 2,772
INVESTMENTS IN AFFILIATED COMPANIES 16,593 15,666
EXCESS OF COST OVER NET ASSETS ACQUIRED -
Net of amortization of $6,503 and $6,357 14,391 14,783
--------- ---------
TOTAL ASSETS $ 207,004 $ 207,002
========= =========
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Notes payable $ 4,354 $ 4,005
Accounts payable 13,525 13,024
Accrued liabilities 5,601 6,057
Income taxes payable 1,306 1,629
--------- ---------
Total current liabilities 24,786 24,715
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Common Stock - no par value, authorized 30,000,000 shares;
outstanding 13,613,818 shares and 13,597,124 shares. 36,874 36,584
Retained earnings 150,610 147,579
Foreign currency translation adjustments (5,266) (1,876)
--------- ---------
Total shareholders' equity 182,218 182,287
--------- ---------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 207,004 $ 207,002
========= =========
2
4
DIAGNOSTIC PRODUCTS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(Dollars in Thousands) Three Months Ended
March 31,
----------------------
1997 1996
-------- --------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income $ 4,663 $ 6,501
Adjustments to reconcile net income to net cash
flows from operating activities:
Depreciation and amortization 3,026 2,927
Equity in undistributed income of
unconsolidated affiliates (281) (445)
Accounts receivable (4,930) (3,251)
Inventories (3,063) (2,556)
Prepaid expenses and other current assets 230 197
Accounts payable 1,523 (2,908)
Accrued liabilities (456) 367
Income taxes payable (277) 499
-------- --------
Net Cash Flows from Operating Activities 435 1,331
CASH FLOWS FROM (USED FOR) INVESTING ACTIVITIES:
Additions to property, plant and equipment (2,761) (1,964)
Sales-type and operating leases (2,354) (1,505)
Investment in affiliated company (646) (481)
-------- --------
Net Cash from (used for) Investing Activities (5,761) (3,950)
CASH FLOWS FROM (USED FOR) FINANCING ACTIVITIES:
Borrowing 669
Proceeds from exercise of stock options 290 265
Cash dividends paid (1,632) (1,624)
-------- --------
Net Cash from (used for) Financing Activities (673) (1,359)
EFFECT OF EXCHANGE RATE CHANGES ON CASH (357) (130)
-------- --------
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (6,356) (4,108)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR 13,781 16,519
-------- --------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 7,425 $ 12,411
======== ========
3
5
DIAGNOSTIC PRODUCTS CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
NOTE 1 -- BASIS OF PRESENTATION
The information for the three months ended March 31, 1997 and 1996 has not been
audited by independent accountants, but includes all adjustments (consisting of
normal recurring accruals) which are, in the opinion of management, necessary to
a fair statement of the results for such periods.
Certain information and footnote disclosure normally included in financial
statements prepared in accordance with generally accepted accounting principles
have been omitted pursuant to the requirements of the Securities and Exchange
Commission, although the Company believes that the disclosures included in these
financial statements are adequate to make the information not misleading.
The consolidated financial statements should be read in conjunction with the
consolidated financial statements and notes thereto included in the Company's
1996 annual report on Form 10-K as filed with the Securities and Exchange
Commission.
The results of operations for the three-month period ending March 31, 1997 are
not necessarily indicative of the results to be expected for the year ended
December 31, 1997.
Net income per share has been computed using the weighted-average number of
common shares and common share equivalents outstanding during each period.
Common share equivalents represent the dilutive effect of outstanding stock
options.
In December 1997, the Company will be required to adopt Statement of Financial
Accounting Standard No. 128, "Earnings per Share." The provisions of this
statement will require a change in the method of calculating earnings per share
which will result in an insignficant difference from currently reported earnings
per share.
NOTE 2 -- INVENTORIES
Inventories by major categories are summarized as follows:
March 31, December 31,
1997 1996
----------- -----------
Raw materials $17,992,000 $14,896,000
Work in process 17,296,000 17,472,000
Finished goods 9,893,000 10,460,000
----------- -----------
Total $45,181,000 $42,828,000
=========== ===========
4
6
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Sales of $44.4 million were achieved in the first quarter of 1997 compared to
$43.2 million in the first quarter 1996, an increase of approximately 3%. Growth
in sales of IMMULITE instrumentation and reagents was partially offset by the
continual decline of the Company's mature RIA product line. Unit sales of
IMMULITE reagents increased 18% over the first quarter of 1996, reflecting the
growing installed base for the system and key new tests introduced during the
past year. In periods when the U.S. dollar is strengthening, the effect of
translation of the financial statements of the consolidated foreign affiliates
is that of lower sales, costs and net income. The stronger U.S. dollar in the
first quarter 1997 when compared to the first quarter 1996 resulted in lower
reported sales of approximately 4 percentage points.
Cost of sales as a percentage of sales was 44% in the 1997 quarter compared to
42% in the 1996 quarter. The increased 1997 costs were primarily the result of
the transactional effect of the strengthening of the U.S. dollar in the first
quarter 1997. The stronger U.S. dollar reduced gross margins by approximately 2
percentage points.
Selling expenditures increased 7% in the 1997 quarter compared to the 1996
quarter representing 20% of sales in 1997 and 19% of sales in 1996. These
increased costs are a result of the continual expansion of the marketing and
sales effort, especially for the IMMULITE systems.
Research and development expenditures increased 8% in the 1997 quarter over
1996. These expenditures have increased to support the IMMULITE systems.
General and administrative expenses increased 19% in the first quarter 1997 over
1996. The increased costs in 1997 resulted primarily from the loss on the
exchange rate recorded by the European subsidiaries on the strengthening of the
U.S. dollar.
Equity in income of affiliates represent the Company's share of earnings of
nonconsolidated affiliates, principally the 45%-owned Italian affiliate.
The Company's effective tax rate includes Federal, state and foreign taxes. The
1997 tax rate of 27% approximates the 1996 rate of 27%.
The Company has adequate working capital and sources of capital (including an
unused $10 million unsecured line of credit) to carry on its current business
and to meet its existing capital requirements. Cash flow from operating
activities was $435,000 in the first quarter 1997 compared to $1.3 million in
the 1996 quarter. Cash flow in the 1997 quarter was primarily used for increases
in accounts receivables and inventories.
The quarterly cash dividend during 1996 and 1997 was $.12 per share.
5
7
PART II. OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
(a) Exhibits
27 Financial Data Schedule
(b) Reports on Form 8-K. None.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DIAGNOSTIC PRODUCTS CORPORATION
(Registrant)
APRIL 24, 1997 SIGI ZIERING
- --------------------------------- ------------------------------------------
Date Sigi Ziering, Ph.D., Chairman of the Board
Chief Executive Officer
APRIL 24, 1997 JULIAN R. BOCKSERMAN
- --------------------------------- ------------------------------------------
Date Julian R. Bockserman, Vice President
Chief Financial Officer
6